Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Employees - 168,
CEO - Mr. Martin Babler Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 265.50M
Altman ZScore(max is 10): -5.83, Piotroski Score(max is 10): 3, Working Capital: $165080000, Total Assets: $261298000, Retained Earnings: $-757514000, EBIT: -354689000, Total Liabilities: $92984000, Revenue: $18907000
AryaFin Target Price - $4.89 - Current Price $4.88 - Analyst Target Price $21.25
| Ticker | ALMS |
| Index | RUT |
| Curent Price | 4.88 |
| Change | -17.98% |
| Market Cap | 265.50M |
| Average Volume | 751.74K |
| Income | -343.35M |
| Sales | 17.39M |
| Book Value/Share | 3.09 |
| Cash/Share | 3.84 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 168 |
| Moving Avg 20days | 3.59% |
| Moving Avg 50days | -8.81% |
| Moving Avg 200days | -42.04% |
| Shares Outstanding | 47.22M |
| Earnings Date | May 14 AMC |
| Inst. Ownership | 35.82% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 15.27 |
| Price/Book | 1.58 |
| Price/Cash | 1.27 |
| Price/FCF | - |
| Quick Ratio | 3.73 |
| Current Ratio | 3.73 |
| Debt/Equity | 0.19 |
| Return on Assets | -156.54% |
| Return on Equity | -247.05% |
| Return on Investment | -173.72% |
| Gross Margin | 81.38% |
| Ops Margin | -1995.45% |
| Profit Margin | -1974.51% |
| RSI | 48.01 |
| BETA(β) | - |
| From 52week Low | 53.46% |
| From 52week High | -63.93% |
| EPS | -6.32 |
| EPS next Year | -3.67 |
| EPS next Qtr | -1.10 |
| EPS this Year | 60.64% |
| EPS next 5 Year | 24.94% |
| EPS past 5 Year | - |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | -93.94% |
| Sales Y/Y | - |
| EPS Q/Q | -89.62% |
| Sales Q/Q | - |
| Sales Surprise | 943.32% |
| EPS Surprise | -22.48% |
| ATR(14) | 0.82 |
| Perf Week | 9.42% |
| Perf Month | 3.83% |
| Perf Quarter | -4.31% |
| Perf Year | - |
| Perf YTD | -37.91% |
| Target Price | 21.25 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer